Dermata Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dermata Therapeutics (DRMA).

Price Target Range — 3 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$10Upside to Avg. PT+1076.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 21, 2025	Maxim Group	Anthony Vendetti	PT Cut	Buy	$30→$10
May 21, 2025	Maxim Group	Anthony Vendetti	PT Cut	Buy	$6→$3
Aug 21, 2024	Maxim Group	Anthony Vendetti	PT Cut	Buy	$10→$6

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $10

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $30 to $10.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $3

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $6 to $3.

Benzinga Newsdesk

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'

U.S. stock futures fell on Friday after two consecutive days of decline on Wednesday and Thursday. Futures of benchmark indices were lower.

Rishabh Mishra

Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday

Avi Kapoor

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $6

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $10 to $6.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $4

Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $16 to $4.

Benzinga Newsdesk

Dermata Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Dermata Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $10

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $3

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'

Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $6

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $4

People Also Watch

People Also Watch

Dermata Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Dermata Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMaxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $10

PROMaxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $3

US Stocks Likely To Open Lower, Analysts Warn 'Prolonged Uncertainty Could Hurt Both US And Global Risk Assets'

Texas Instruments To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Wednesday

PROMaxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $6

PROMaxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $4

People Also Watch

People Also Watch

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $10

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $3

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $6

PRO
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $4